Ishii, Masanobu
,
Seki, Tomotsugu
Kaikita, Koichi
Sakamoto, Kenji
Nakai, Michikazu
Sumita, Yoko
Nishimura, Kunihiro
Miyamoto, Yoshihiro
Noguchi, Teruo
Yasuda, Satoshi
Tsutsui, Hiroyuki
Komuro, Issei
Saito, Yoshihiko
Ogawa, Hisao
Tsujita, Kenichi
Kawakami, Koji
Funding for this research was provided by:
the Minister of Education, Science, Sports and Culture
Japan Society for the Promotion of Science (JP19K17531)
Article History
Received: 27 July 2019
Accepted: 8 January 2020
First Online: 16 January 2020
Compliance with ethical standards
:
: All authors declare no potential conflict of interest in connection with this paper and have completed the ICMJE uniform disclosure form at ExternalRef removed and declare: Dr. Seki reports personal fees from Pfizer.inc., outside the submitted work. Dr. Kaikita reports grants and other from Bayer Yakuhin, Ltd., grants and other from Daiichi Sankyo Co., Ltd., grants from Novartis Pharma K.K., grants from SBI pharma K.K., from null, outside the submitted work. Dr. Sakamoto reports grants from Daiichi-Sankyo Co., Ltd., outside the submitted work. Dr. Yasuda reports grant support from Takeda and Abbott, and lecture fees from Daiichi Sankyo and Bristol-Myers Squibb. Dr. Saito reports grants and personal fees from Bayer Holding Ltd, grants from Terumo Corporation, grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants from Amgen Astellas BioPharma K.K., grants and personal fees from Novartis Pharma K.K., grants and personal fees from Ono Pharmatical Co., Ltd, grants and personal fees from Shionogi & Co., Ltd, grants and personal fees from Teijin Pharma Ltd., grants from St. Jude Medical Japan Co., Ltd., grants and personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from Astellas Pharma Inc., personal fees from Asahi Kasei Pharma Corporation, personal fees from Actelion Pharmaceuticals Japan Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Daiichi Sankyo Co., Ltd., personal fees from Dainippon Sumitomo Pharma Co., Ltd., personal fees from Eisai Co., Ltd., personal fees from Fuji Yakuhin Co., Ltd., personal fees from Kowa Pharmaceutical Co., Ltd, personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from Medtronic, Inc., personal fees from MSD K.K. a subsidiary of Merck & Co., Inc., personal fees from Nihon Medi-Physics Co.,Ltd., personal fees from Sanofi K.K., personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from ZERIA Pharmaceutical Co., Ltd., personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Pfizer Japan Inc., personal fees from Taisho Toyama Pharmaceutical Co., Ltd., personal fees from Toa Eiyo LTD., outside the submitted work. Dr. Tsutsui reports personal fees from Novartis Pharma K.K., personal fees from Pfizer Japan Inc., personal fees from Bayer Yakuhin, Ltd., personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Daiichi Sankyo Co., Ltd., personal fees from MSD K.K., personal fees from Mitsubishi Tanabe Pharm Corp., personal fees from Teijin Pharm Ltd., personal fees from Bristol-Myers Squibb Company, personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from Otsuka Pharmaceuticals Co., Ltd., personal fees from Astellas Parma Inc., outside the submitted work. Dr. Komuro reports grants from Otsuka Pharmaceuticals Co., Ltd., grants and personal fees from Daiichi Sankyo Co., Ltd., grants from Dainippon Sumitomo Pharma Co., Ltd., grants and personal fees from Takeda Pharmaceutical Co., Ltd., grants from Teijin Pharm Ltd., grants from Toa Eiyo LTD., personal fees from Astellas Pharma Inc., personal fees from AstraZeneca K.K., personal fees from MSD K.K., personal fees from Ono Pharmatical Co., Ltd, personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Bayer Yakuhin, Ltd., personal fees from Pfizer Japan Inc., outside the submitted work; Dr. Tsujita reports personal fees from Novartis Pharma K.K., personal fees from Bayer Yakuhin, Ltd., personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Daiichi Sankyo Co., Ltd., personal fees from MSD K.K., personal fees from Mitsubishi Tanabe Pharm Corp., grants from Teijin Pharm Ltd., personal fees from Bristol-Myers Squibb Company, personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from Otsuka Pharmaceuticals Co., Ltd., personal fees from Astellas Parma Inc., grants from AstraZeneca K.K., personal fees from Sanofi K.K., personal fees from Cardinal Health Japan Inc., personal fees from Goodman Co.,LTD., personal fees from Chugai Pharmaceutical Co, Ltd., personal fees from Boston Scientific Japan K.K., personal fees from Kowa Pharmaceutical Co. Ltd., personal fees from Pfizer Japan Inc., personal fees from Shionogi & Co., outside the submitted work. Dr. Kawakami reports personal fees from Shin Nippon Biomedical Laboratories, Ltd., other from School Health Record Center Co.,Ltd., other from Real World Data, Co., Ltd., grants from Olympus Corporation, grants from Bayer Yakuhin, Ltd., grants from Cmic Co., Ltd., grants from Novartis Pharma K.K., grants from Suntory Beverage & Food Limited, grants from Sumitomo Dainippon Pharma Co., Ltd., grants from Medical Platform Co. Ltd., grants from STELLA PHARMA CORPORATION, grants from Amgen Astellas BioPharma K.K., outside the submitted work. Other authors declare no potential conflict of interest.